About Biomarkers
Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.
Technavio’s analysts forecast the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global neurological biomarkers market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of neurological biomarkers.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Neurological Biomarkers Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Myriad RBM
• Proteome Sciences
• QIAGEN
• Thermo Fisher Scientific
Other prominent vendors
• AbaStar MDx
• Abiant
• Acumen Pharmaceuticals
• Aepodia
• Alseres Pharmaceuticals
• Athena Diagnostics
• Banyan Biomarkers
• Cisbio Bioassays
• Diagenic
• Proteosys
• Psynova Neurotech
Market driver
• Increasing focus toward drug discovery applications
• For a full, detailed list, view our report
Market challenge
• Unmet market needs of effective validation of biomarkers
• For a full, detailed list, view our report
Market trend
• Integrated biology approach will be the key focus area
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Biomarker assays kits
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis:
PART 06: Market segmentation by indication
• AD
• PD
• ASD
• MS
PART 07: Market segmentation by application
• Genomics-based biomarkers
• Proteomics-based biomarkers
• Metabolomics-based biomarkers
• Imaging-based biomarkers
• Emerging application areas
PART 08: Market segmentation by services
• Services
PART 09: Market segmentation by end-user
• Hospitals
• Diagnostic and research laboratories
PART 10: Geographical segmentation
• Neurological biomarkers market in Americas
• Neurological biomarkers market in EMEA
• Neurological biomarkers market in APAC
PART 11: Market drivers
• Increasing low-cost clinical trials in developing countries
• Growing personalized medicine for neurological disorders
• Increasing focus toward drug discovery applications
PART 12: Impact of drivers
PART 13: Market challenges
• Unmet market needs of effective validation of biomarkers
• Reproducibility of biomarkers and tests leading to discrepancies
• Delay in market launch
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Integrated biology approach will be the key focus area
• Development of novel radiotracers for neuro biomarkers that aid diagnostic and clinical applications for diseases
• Evolution of miRNA
PART 16: Vendor landscape
• Competitive scenario
PART 17: Key vendor analysis
• Geographic presence — Key vendor analysis
• Myriad RBM
• Proteome Sciences
• QIAGEN
• Thermo Fisher Scientific
• Other prominent vendors
PART 18: Appendix
• List of abbreviations
PART 19: Explore Technavio
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key biomarker technology platforms
Exhibit 03: Global neurological biomarkers market (2016-2020) ($ billions)
Exhibit 04: Five forces analysis
Exhibit 05: Market segmentation by indication
Exhibit 06: Market opportunities in the major indications
Exhibit 07: Global neurological biomarkers market segmentation by application 2015
Exhibit 08: Market opportunities in key applications
Exhibit 09: Impact mapping of neurological biomarker services
Exhibit 10: Opportunity analysis of biomarker services
Exhibit 11: Global neurological biomarkers market 2015
Exhibit 12: Market overview in Americas 2015
Exhibit 13: Neurological biomarkers market in Americas ($ billions)
Exhibit 14: Market overview in EMEA 2015
Exhibit 15: Neurological biomarkers market in EMEA ($ billions)
Exhibit 16: Market overview in APAC 2015
Exhibit 17: Neurological biomarkers market in APAC ($ millions)
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: Competitive structure analysis of global neurological biomarkers market 2015
Exhibit 21: Market penetration of key neurological biomarkers manufacturers 2015
Exhibit 22: Strategic success factors of companies in global neurological biomarkers market
Exhibit 23: Regional analysis of key vendors
Exhibit 24: Myriad RBM: Profile
Exhibit 25: Myriad RBM: Strength analysis
Exhibit 26: Myriad RBM: Growth strategy matrix
Exhibit 27: Myriad RBM: Opportunity assessment analysis
Exhibit 28: Proteome Sciences: Profile
Exhibit 29: Proteome Sciences: Strength analysis
Exhibit 30: Proteome Sciences: Growth strategy matrix
Exhibit 31: Proteome Sciences: Opportunity assessment
Exhibit 32: QIAGEN: Profile
Exhibit 33: QIAGEN: Strength analysis
Exhibit 34: QIAGEN: Growth strategy matrix
Exhibit 35: QIAGEN: Opportunity assessment
Exhibit 36: Thermo Fisher Scientific: Profile
Exhibit 37: Thermo Fisher Scientific: Strength analysis
Exhibit 38: Thermo Fisher Scientific: Growth strategy matrix
Exhibit 39: Thermo Fisher Scientific: Growth opportunity assessment
